Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LX2020 · 1 trial · 3 indications
Evaluation of Safety and Tolerability of LX2020
| Arm | Type | Description |
|---|---|---|
| LX2020 | EXPERIMENTAL | Single ascending dose of LX2020, with a starting dose of 2.0 x10\^13 gc/kg, in multiple cohorts |
| Name | Type | Description |
|---|---|---|
| LX2020 | GENETIC | LX2020 is an adeno-associated viral vector encoding the human Plakophilin-2 (PKP2) gene (AAVrh.10hPKP2) |
Selected Inclusion Criteria: * Adults with a clinical diagnosis of ACM meeting the 2010 revised Task Force Criteria (TFC) * Genetic testing documenting a pathogenic or likely pathogenic variant in PKP2 * Frequent premature ventricular complexes (PVCs) * Implantable cardioverter-defibrillator (ICD) ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | 3 | PHASE1 | LX2020 |
LX2020 is an investigational gene therapy being developed for arrhythmogenic cardiomyopathy, a rare heart condition. It is designed to treat patients with a PKP2 pathogenic variant, which is a genetic cause of the disease. The therapy is currently in Phase 1 clinical development.
LX2020 targets the PKP2 gene. It is a gene therapy intended to address arrhythmogenic cardiomyopathy caused by a PKP2 pathogenic variant. By targeting this genetic cause, the therapy aims to treat the underlying condition.
LX2020 is being developed by Lexeo Therapeutics, Inc., a biopharmaceutical company. Lexeo Therapeutics is publicly traded under the ticker symbol LXEO on the stock market.
LX2020 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy.
LX2020 is being studied in a Phase 1 clinical trial with the identifier NCT06109181. This trial is titled 'Gene Therapy for ACM Due to a PKP2 Pathogenic Variant' and is currently active but not recruiting participants. The trial is enrolling 10 participants in the United States.
LX2020 is not the same as PKP2-ACM. PKP2-ACM is a condition, specifically arrhythmogenic cardiomyopathy caused by a PKP2 pathogenic variant. LX2020 is an investigational gene therapy being developed to treat this condition.